BACKGROUND: Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- or 2-dose schedules. We examined HPV vaccine effectiveness against HPV prevalence by number of doses. METHODS: We collected residual liquid-based cytology samples from US women aged 20-29 years who were screened for cervical cancer. Women continuously enrolled from 2006 through the specimen collection date were analyzed. Specimens were tested using the Linear Array assay. We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18) and other HPV-type categories and determined prevalence ratios (PRs) and 95% confidence intervals (CIs) for 1, 2, and 3 compared with no vaccine doses. RESULTS: Among 4269 women, 1052 (24.6%) were unvaccinated, 2610 (61.1%) received 3 doses, 304 (7.1%) received 2 doses, and 303 (7.1%) received 1 dose. The 4vHPV-type prevalence was 7.4% among unvaccinated women compared with 1.7%, 1.0%, and 1.0% among 1-, 2-, and 3-dose recipients. Among women vaccinated at ≤18 years, adjusted PRs for 1, 2, and 3 doses were 0.06 (95% CI, 0.01-0.42), 0.05 (95% CI, 0.01-0.39), and 0.06 (95% CI, 0.04-0.12). CONCLUSIONS: Among women who received their first dose at age ≤18, estimated HPV vaccine effectiveness was high regardless of number of doses. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- or 2-dose schedules. We examined HPV vaccine effectiveness against HPV prevalence by number of doses. METHODS: We collected residual liquid-based cytology samples from US women aged 20-29 years who were screened for cervical cancer. Women continuously enrolled from 2006 through the specimen collection date were analyzed. Specimens were tested using the Linear Array assay. We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18) and other HPV-type categories and determined prevalence ratios (PRs) and 95% confidence intervals (CIs) for 1, 2, and 3 compared with no vaccine doses. RESULTS: Among 4269 women, 1052 (24.6%) were unvaccinated, 2610 (61.1%) received 3 doses, 304 (7.1%) received 2 doses, and 303 (7.1%) received 1 dose. The 4vHPV-type prevalence was 7.4% among unvaccinated women compared with 1.7%, 1.0%, and 1.0% among 1-, 2-, and 3-dose recipients. Among women vaccinated at ≤18 years, adjusted PRs for 1, 2, and 3 doses were 0.06 (95% CI, 0.01-0.42), 0.05 (95% CI, 0.01-0.39), and 0.06 (95% CI, 0.04-0.12). CONCLUSIONS: Among women who received their first dose at age ≤18, estimated HPV vaccine effectiveness was high regardless of number of doses. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Entities:
Keywords:
HPV prevalence; HPV vaccine; human papillomavirus; vaccine effectiveness
Authors: Elissa Meites; Rachel L Winer; Michael E Newcomb; Pamina M Gorbach; Troy D Querec; Jessica Rudd; Tom Collins; John Lin; Janell Moore; Thomas Remble; Fred Swanson; Justin Franz; Robert K Bolan; Matthew R Golden; Brian Mustanski; Richard A Crosby; Elizabeth R Unger; Lauri E Markowitz Journal: J Infect Dis Date: 2020-11-13 Impact factor: 5.226
Authors: Janita Pak Chun Chau; Suzanne Hoi Shan Lo; Laveeza Butt; Vivian Wing Yan Lee; Grace Chung Yan Lui; Alexander Yuk Lun Lau Journal: J Cancer Educ Date: 2022-07-06 Impact factor: 2.037
Authors: Susan Yuill; Louiza S Velentzis; Megan Smith; Sam Egger; C David Wrede; Deborah Bateson; Marc Arbyn; Karen Canfell Journal: Hum Vaccin Immunother Date: 2021-10-03 Impact factor: 4.526
Authors: Rayleen M Lewis; Allison L Naleway; Nicola P Klein; Bradley Crane; Amber Hsiao; Laurie Aukes; Julius Timbol; Troy D Querec; Martin Steinau; Sheila Weinmann; Elizabeth R Unger; Lauri E Markowitz Journal: J Low Genit Tract Dis Date: 2022-04-01 Impact factor: 3.842
Authors: Zheng Quan Toh; Fiona M Russell; Suzanne M Garland; Edward K Mulholland; George Patton; Paul V Licciardi Journal: JNCI Cancer Spectr Date: 2021-03-02
Authors: Luca De Toni; Francesco Muscianisi; Christian Corsini; Marco Ghezzi; Andrea Di Nisio; Carlo Foresta; Andrea Garolla Journal: Vaccines (Basel) Date: 2020-12-07